Phase 1 dose escalation of H3B-6545, a potential first-in-class Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast… Read More »
Presentations highlight company’s expertise seamlessly integrating human biology, data science and modern chemistry to advance a pipeline of investigational breakthrough… Read More »
Next-generation endocrine therapy exhibits differentiated mechanism of action versus standard-of-care therapies and potently inhibits the ERα pathway H3 Biomedicine’s first… Read More »
Expands potential addressable patient population for H3 Biomedicine’s lead splicing modulator H3B-8800, currently in Phase 1 study for other hematologic… Read More »
A partnership announced today between two Cambridge companies, Foundation Medicine (Nasdaq: FMI) and H3 Biomedicine, is further evidence of the… Read More »
Genomic analyses of cancer have identified recurrent point mutations in the RNA splicing factor–encoding genes SF3B1, U2AF1, and SRSF2 that… Read More »
Muscle-invasive bladder cancer (MIBC) is an aggressive disease with limited therapeutic options. Although immunotherapies are approved for MIBC, the majority… Read More »
Pladienolide, herboxidiene and spliceostatin have been identified as splicing modulators that target SF3B1 in the SF3b subcomplex. Here we report… Read More »
For all media interested in speaking to members of H3 Biomedicine’s executive/scientific team, or receiving further information about the company or pipeline, please forward your request to Liz Melone.